Roche intends to seek U.S. approval for cobimetinib later this year.
Healthcare investors (and traders) have had a lot to work with so far this year, and the next six months promises to be equally action packed.
Even with greater decline in walk performance after almost three years, Duchenne boys treated with eteplirsen are still benefiting from treatment, Sarepta says.
The SEC halts trading in Radient Pharmaceuticals.
Provectus Biopharmaceuticals issued a "CEO Letter" Tuesday regurgitating all the recent spin and ridiculously unrealistic talking points about the company's experimental (but already obsolete) melanoma therapy PV-10.
Sarepta is selling off Monday on new worries about eteplirsen efficacy. Of course, these are really just old worries, recycled.
Lief's $1.3 million sale of Arena shares was disclosed in an SEC filing last week.
The hip waders I normally wear for protection from biotech bullshit aren't tall enough to wade through Ampio's current press release. I need a full haz-mat suit.
Investors aren't yet recognizing Vertex's ability to develop triple-combo therapies for hardest-to-treat cystic fibrosis patients.
A phase II study of Squalamine in wet age-related macular degeneration bombed badly.